| ID | 10011 |
| Vaccine Name | Zifivax |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Approved |
| Manufacturer | Anhui Zhifei Longcom Biologic Pharmacy Co. Ltd. |
| Year of Manufacturing | 2020 |
| Manufacturing Country | China |
| Age | NA |
| Dosage | 2 doses 2 to 3 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | SARS-CoV-2 receptor-binding domain from spike protein |
| Description | NA |
| Approving Organisation | China FDA |
| Collaborating Organisation | Institute of Microbiology of the Chinese Academy of Sciences |
| Other Countries | China, Uzbekistan, Indonesia, Pakistan, Ecuador |
| Trade Name | RBD-Dimer, ZF2001 |
| PMID | 33816047 |
| Clinical Trial ID | NCT04646590 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT05091411
|